Evidence map›Paper›PMID 39704796›Full record

ArticleSkeletal radiology2025

Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.

William C Ou, Jack W Jennings, Benjamin E Northrup, Gino M Dettorre, Winston L Winkler, Resten Imaoka, Theodore L Vander Velde, Barry A Siegel

Abstract read
PubMed Publisher
In one paragraph

Article in Skeletal radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William C OuMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA. ouw@wustl.edu.ORCID http://orcid.org/0000-0003-1997-1360
Jack W JenningsMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Benjamin E NorthrupMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Gino M DettorreMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Winston L WinklerMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Resten ImaokaMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Theodore L Vander VeldeMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Barry A SiegelMallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProstate-specific membrane antigen (PSMA)-PET/CT has shown considerable promise in the evaluation of prostate cancer bone metastases; however, data utilizing a histopathologic reference standard in this setting are limited. We therefore sought to evaluate the diagnostic performance of PSMA-PET/CT using a consistent histopathologic gold standard in the form of bone biopsy. MATERIALS AND

methodsIn this single-center, retrospective study, we identified 80 patients with prostate cancer who underwent CT-guided bone biopsy of a tracer-avid osseous lesion on PSMA-PET/CT performed with

resultsPSMA-PET/CT and bone biopsy results were concordant in 55/80 patients (69%), and the positive predictive value of PSMA-PET/CT for osseous metastasis of prostate cancer was 66% (53/80). Positive predictive values for spine, pelvis, and rib biopsies were 82% (23/28), 72% (18/25), and 26% (5/19), respectively. Peak SUV and its ratio to liver mean SUV were significantly higher in biopsy-positive lesions compared to biopsy-negative lesions. A threshold peak SUV to liver mean SUV ratio of 1.7 had a sensitivity of 61% and a specificity of 92% for a histopathologic diagnosis of metastatic prostate cancer.

conclusionPSMA-PET/CT has a moderately high histopathologic concordance and positive predictive value for the diagnosis of osseous metastatic disease in prostate cancer. Peak SUV is useful for distinguishing biopsy-positive from biopsy-negative lesions. In keeping with prior investigations, a majority of biopsied rib lesions were negative for metastatic prostate cancer.

Indexed as

Bone NeoplasmsPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overAntigens, SurfaceBiopsyGlutamate Carboxypeptidase IIHumansMaleMiddle AgedPredictive Value of TestsRadiopharmaceuticalsRetrospective StudiesSensitivity and SpecificityAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticalsBone biopsyPeak SUVProstate cancerPSMA-PET/CT

Identifiers

PMID39704796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.